Reading TDOC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TDOC free→Reading TDOC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TDOC free→NYSEHealth CareHealth Information ServicesSnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral. Earnings quality is not assessable since the company is unprofitable. Management's recent track record has been fairly steady. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, TDOC trades above typical levels. Peer multiples imply a price about 63% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern suggests potential issues due to weak financials or fragile earnings quality. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $7.46. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $7.46 TDOC trades at 1× p/s, below its 2× p/s peer median. Our $21 fair value sits above the price; low confidence. Analysts: $6.00–$11. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 64% below a flat-multiple fair value, below our forecast of about 1%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted -1.68x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.24 → $-0.24 (+0.0% / 30d). 0 raised, 2 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 27% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$217.
How much price usually moves either way.
On a bad day, this stock has moved -$553.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,275.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If healthcare sector growth speeds up, it could benefit Teladoc. This would signal a stronger market environment.
Confirms:Healthcare sector revenue growth exceeds 12% year over year.
Disproves:Healthcare sector revenue growth stays below 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for TDOC yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On April 29, 2026, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the first quarter of 2026. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$6.00 – $11.00 (median $6.00) · 4 analysts · as of 2026-04-08
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
TDOC Teladoc Health, Inc. | Above typical Show detailsSector percentile: 81 of 100 | inexpensive | elevated |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 78 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
DOCS Doximity | Above typical Show detailsSector percentile: 80 of 100 | full | high |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Teladoc aims to achieve its full-year 2026 revenue guidance range of $2,481 to $2,576 million.
Newly stated in 2026-Q1. Revenue was $613.8 million in 2026-Q1. To meet the full-year guidance, Teladoc needs to maintain or increase this quarterly revenue level. The trajectory is uncertain as this is a new target.
“For the full year of 2026, we expect: Full Year 2026 Outlook Range Revenue $2,481 - $2,576 million.”
Teladoc aims to reduce its net loss per share to between $0.75 and $1.05 for the full year 2026.
Newly stated in 2026-Q1. Net income was -$63.8 million in 2026-Q1, indicating a significant loss. Achieving the net loss per share target will require substantial cost management and revenue growth. The trajectory is uncertain as this is a new target.
Teladoc aims to achieve its Q2 2026 revenue guidance range of $597 to $626 million.
Newly stated in 2026-Q1. Revenue was $613.8 million in 2026-Q1, which is within the Q2 2026 guidance range. The trajectory appears on track to meet the Q2 target if current revenue levels are maintained.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective March 30, 2026, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Susan R. Salka as a director of the Company. Ms. Salka was additionally appointed to each of the audit committee and the compensation committee of the Board. The Board has determ…
Results of Operations and Financial Condition. On February 25, 2026, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the fourth quarter and full year 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective February 18, 2026, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Michael S. Smith as a director of the Company. Mr. Smith was additionally appointed to each of the audit committee and the nominating and corporate governance committee of the…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 8, 2026, Mr. Thomas G. McKinley notified Teladoc Health, Inc. (the “Company”) of his intention to retire from the Board effective as of February 20, 2026. Mr. McKinley has been a director of the Company since 2009 and the Company thanks him for his dedicated service. Mr. McKinley has indicated that he is retiring from the Board for pers…
“For the full year of 2026, we expect: Net loss per share ($1.05) - ($0.75).”
“For the second quarter of 2026, we expect: 2Q 2026 Outlook Range Revenue $597 - $626 million.”